In Vivo Predictive Dissolution: Comparing the Effect of Bicarbonate and Phosphate Buffer on the Dissolution of Weak Acids and Weak Bases by Krieg, Brian J. et al.
RESEARCH ARTICLE – Pharmaceutics, Drug Delivery and Pharmaceutical Technology
In Vivo Predictive Dissolution: Comparing the Effect of Bicarbonate
and Phosphate Buffer on the Dissolution of Weak Acids and
Weak Bases
BRIAN J. KRIEG,1 SEYED MOHAMMAD TAGHAVI,2 GORDON L. AMIDON,1 GREGORY E. AMIDON1
1College of Pharmacy, University of Michigan, Ann Arbor Michigan 48109
2Department of Chemical Engineering, Laval University, Quebec, Quebec City G1V 0A6, Canada
Received 30 October 2014; revised 29 March 2015; accepted 1 April 2015
Published online 15 May 2015 in Wiley Online Library (wileyonlinelibrary.com). DOI 10.1002/jps.24460
ABSTRACT: Bicarbonate is the main buffer in the small intestine and it is well known that buffer properties such as pKa can affect the
dissolution rate of ionizable drugs. However, bicarbonate buffer is complicated to work with experimentally. Finding a suitable substitute
for bicarbonate buffer may provide a way to perform more physiologically relevant dissolution tests. The dissolution of weak acid and weak
base drugs was conducted in bicarbonate and phosphate buffer using rotating disk dissolution methodology. Experimental results were
compared with the predicted results using the film model approach of (Mooney K, Mintun M, Himmelstein K, Stella V. 1981. J Pharm Sci
70(1):22–32) based on equilibrium assumptions as well as a model accounting for the slow hydration reaction, CO2 + H2O → H2CO3.
Assuming carbonic acid is irreversible in the dehydration direction: CO2 + H2O ← H2CO3, the transport analysis can accurately predict
rotating disk dissolution of weak acid and weak base drugs in bicarbonate buffer. The predictions show that matching the dissolution of
weak acid and weak base drugs in phosphate and bicarbonate buffer is possible. The phosphate buffer concentration necessary to match
physiologically relevant bicarbonate buffer [e.g., 10.5 mM (HCO3−), pH = 6.5] is typically in the range of 1–25 mM and is very dependent
upon drug solubility and pKa. C© 2015 Wiley Periodicals, Inc. and the American Pharmacists Association J Pharm Sci 104:2894–2904,
2015
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equilibria
INTRODUCTION
Dissolution can be an important diagnostic tool for predicting
the in vivo effects when a drug product is administered orally.
The identification of an in vitro dissolution test that accurately
predicts in vivo dissolution is therefore essential. Bicarbonate
(HCO3−) is secreted by the pancreas and epithelial cells in the
small intestine to neutralize gastric acid emptied into the duo-
denum and buffer the intestinal fluid maintaining intestinal
pH. Conducting dissolution experiments in bicarbonate buffer
would be more physiologically realistic. However, the prepara-
tion of physiologically relevant bicarbonate buffer is complex
experimentally. CO2 gas must be constantly added to water to
obtain a constant bicarbonate buffer concentration. This is gen-
erally a slow process that can also affect the hydrodynamics and
dissolution of drug product/particles because of the potential
presence of gas bubbles at solid–liquid interfaces. Therefore,
using a buffer solution that produces equivalent buffer effect
on drug dissolution as bicarbonate buffer would be preferred.
Phosphate buffer is a logical buffer to consider to match the
effect of bicarbonate buffer on dissolution. It is commonly used
in dissolution testing and is a buffer proposed by US FDA to
be used for in vivo biowaivers.1 The relevant pKa of phosphate
(6.8) is within the pH range of the small intestine and therefore
makes it a suitable buffer to be considered for physiologically
relevant dissolution tests. Additionally, the dissolution of weak
acid drugs has been accurately predicted in phosphate buffer
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using the film model and reaction plane model.2–4 Therefore,
there is already precedence for making accurate predictions
of dissolution in phosphate buffer that is further supported in
this paper. This work provides greater insight by using a wide
range of phosphate buffer concentrations to match dissolution
in bicarbonate buffer.
Phosphate buffer is currently used today as the buffer
component in USP simulated intestinal fluid at pH 6.8, and
in fasted-state simulated intestinal fluid at pH 6.5 with
concentrations/buffer capacities of 50 mM/29 mM/pH and
29 mM/15 mM/pH, respectively.5,6 In comparison, the aver-
age bicarbonate buffer concentrations in the small intestine
are approximately 6–20 mM that correspond to a buffer capac-
ity range of 2.5–8.5 mM/pH at a pH of 6.5.7 This calculated
buffer capacity corresponds very well with reported data for
measured buffer capacities in human intestinal fluid that are
within this same range of 2.48–13 mM/pH.8–12 The differ-
ence in physiological bicarbonate buffer concentration/capacity
compared with typical phosphate buffer concentration/capacity
highlights the difference between the dissolution media that is
currently used compared with the fluid present in the small
intestine. These differences have been studied experimentally
and significant differences in dissolution between physiologi-
cally relevant bicarbonate buffer and phosphate buffer have
been observed.4,13–16 However, the differences observed in the
dissolution rates are not only caused by the different buffer con-
centration/capacity used in the dissolution experiments. The
physicochemical properties of the drug will impact the pH
at the surface of the dissolving drug that makes matching
dissolution rates in two different buffer systems more com-
plex than matching buffer capacities in the bulk solution. The
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physicochemical properties of the drug and buffer must be
taken into account to accurately predict how a drug will dis-
solve in each buffer system.
Krieg et al.17 have demonstrated the importance of reaction
kinetics on the ability of bicarbonate to buffer the bulk aqueous
pH as well as the pH at the surface of the dissolving drug. These
reaction rate considerations introduce an additional complex-
ity for matching the buffer capacities of bicarbonate and phos-
phate.
In the bulk aqueous phase where equilibrium conditions
may be assumed, the buffer capacity of the CO2–bicarbonate
buffer behaves according to Reaction (1) with a buffer pKa of
6.04 (Bulk Chemical Equilibrium model: BCE model). This
equilibrium is achieved in the bulk solution because the
chemical reactions have an extended period of time to take
place.
CO2 (aq)+H2O H2CO3  H+ +HCO−3 (Reaction 1)
However, in the aqueous boundary layer and at the sur-
face of dissolving drug, the reaction rate kinetics are crit-
ically important to consider and it was shown by Krieg et
al.17 that the CO2–bicarbonate buffer behave according to
Reaction (2).
CO2 (aq)+H2O ← H2CO3  H+ +HCO−3 (Reaction 2)
In the diffusion layer, the reaction between CO2 and H2O to
form carbonic acid occurs at a sufficiently slow rate that it will
effectively not occur to a significant extent in the short resi-
dence time in the diffusion layer (0.5 s). Therefore, the buffer
capacity of bicarbonate in the diffusion layer will be governed
by Reaction (2) (irreversible reaction rate model: IRR model).
Because of the differences in these two reaction schemes, one
can consider bicarbonate buffer as behaving as two different
buffers: the bulk equilibrium buffer (Reaction (1)) and a dy-
namic, irreversible reaction rate buffer (IRR) in the diffusion
layer. As a result of these considerations, low buffer capacities
may be required by the equivalent phosphate buffer to match
bicarbonate buffer, and external control of pHmay be necessary
to maintain the pH of the bulk solution.
This paper will experimentally examine the buffer effects of
phosphate and bicarbonate using rotating disk dissolution of
weak acid and weak base drugs and demonstrate a process for
selecting an equivalent phosphate buffer based on drug solubil-
ity and pKa properties. The experimental data will be compared
with predictions and the results will show that the dissolu-
tion of both weak acid and weak base drugs can be accurately
predicted in buffers with different physicochemical properties.
Also, the dissolution data will illustrate the impact of the slow
CO2 hydration reaction and howmatching other buffer systems
to bicarbonate is more complex than simply matching bulk so-
lution buffer capacities. These results may provide the basis
for predicting phosphate buffer concentrations that are more
indicative of the buffer present in the luminal fluid of the in-
testine and offer a more physiologically relevant dissolution
buffer.
Applying a Simultaneous Diffusion and Reaction Model to
Phosphate Buffer
Phosphate buffer properties are determined by the following
ionization reactions:
H3PO4
Ka1
 H2PO−14 pKa1 = 1.86 (Reaction 3)
H2PO
−1
4
Ka2
 HPO−24 pKa2 = 6.8 (Reaction 4)
HPO−24
Ka3
 PO−34 pKa3 = 11.5 (Reaction 5)
At physiologically relevant pH values of the small intes-
tine, the only relevant pKa value is 6.8 (pKa2) as demon-
strated by Aunins et al.2 who incorporated buffers with multi-
ple pKa values into the simultaneous diffusion and chemical
reaction model. The values for pKa1 (1.86) and pKa3 (11.5)
are not in the range of the physiologically relevant intesti-
nal pH and therefore have no significant buffer effects. There-
fore, the only species of relevance are monobasic phosphate
and dibasic phosphate (Reaction (4)). This point stresses the
importance of having pKa values that are consistent with the
properties used in the bulk solution. The ionic strength of the
solution can alter the pKa of a buffer or drug. Therefore, hav-
ing measurements or literature values for pKa at similar ionic
conditions to the dissolution medium is important to assess
how the buffer and drug will alter the pH in the diffusion
layer. For Reactions (3)–(5), the reaction rates for ionization
are assumed to be occurring so fast that they occur instanta-
neously relative to diffusion. Therefore, the film model accu-
rately predicts the impact of phosphate buffer on the dissolu-
tion of weak acid drugs as described by Mooney et al.19 and
Aunins et al.2
In this paper, the same film model procedure is applied to
weak base drugs. In contrast to a weak acid, a weak base drug
will protonate at pH values below its pKa and consequently it
will produce OH− in solution. As a result, the pH at the sur-
face of a weak base drug will generally be higher than that
of the bulk solution pH. Hence, the chemical equilibrium re-
actions must take this into account. The equilibrium reactions
are shown below.
H+ +OH−
Kw
 H2O (Reaction 6)
B− +H2O
KDb
 BH+OH− (Reaction 7)
B− +H+
K∗1
 BH+H2O (Reaction 8)
B− +H2PO−4
K2
 BH+HPO−24 (Reaction 9)
HPO−24 +H2O
KBb
 H2PO−4 +OH− (Reaction 10)
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where B− is the deprotonated form of the weak base drug and
BH is the protonated form of the weak base drug.
The assumptions made in the film model for weak acids are
applied here to weak bases for the first time with the chem-
ical equilibrium adjusted accordingly. The main assumptions
are that the species in the diffusion layer acting as acids must
be equal to the species acting as bases, drug cannot be cre-
ated or destroyed, and that charge neutrality is maintained
throughout the diffusion layer. The assumptions simplify the
differential equations and allow for the pH at the surface to be
calculated. For example, the electrical neutrality assumption is
defined by setting the sum of the flux of the negatively charged
species equal to the sum of the flux of the positively charged
species. These assumptions couple diffusion and charge neu-
trality. There is also an assumption that the diffusion coeffi-
cient of each species is the same in the bulk solution as it is
in the diffusion layer. Literature has shown that this assump-
tion may not be accurate as varying the concentration of ions
in solution can impact the diffusivity of a species.20 However,
the bulk solution was made isotonic by adding sodium chloride.
This should make the concentration of ions relatively constant
throughout because the presence of the drug in the diffusion
layer will only minimally change the total ion concentration.
Solving the associated differential equations in the manner
of Mooney et al.,19 a cubic equation can be obtained for the
OH− concentration at the surface of the tablet that then allows
the pH at the surface of the tablet to be calculated. This cubic
equation is shown below.
p[OH−]30 + q[OH−]20 + r[OH−]0 + s= 0 (1)
p = DOHDHPO4
q= DOHDH2PO4KBb +DHPO4DH
[
H+
]
h
+DHPO4DH2PO4
[
H2PO
−
4
]
h −DHPO4DOH
[
OH−
]
h
r= DH2PO4DHKBb
[
H+
]
h +D2H2PO4KBb
[
H2PO
−
4
]
h
−DH2PO4DOHKBb
[
OH−
]
h −D2H2PO4KBb
[
H2PO
−
4
]
h
−DH2PO4DHPO4KBb
[
HPO−24
]
h
−DBHDHPO4KDb
[
B−
]
0
−DHDHPO4Kw
s= −DBHDH2PO4KDb KBb
[
B−
]
0 −DHDH2PO4KwKBb
This same transport analysis assuming instantaneous chem-
ical equilibrium may be applied to bicarbonate buffer as de-
scribed by Krieg et al.17 The BCE model assumes that the
hydration and dehydration reactions in the formation of bi-
carbonate are fast enough to reach chemical equilibrium in-
stantaneously (Reaction (1)): pKa = 6.04). The carbonic acid
ionization (CAI) model assumes that the hydration and dehy-
dration reactions are too slow to occur at all in the diffusion
layer (H2CO3H+ +HCO−3 : pKa = 3.55). A thorough explanation
of these models for weak acid drugs is given in Krieg et al.17
Applying a Simultaneous Diffusion and Reaction Model with an
Irreversible Chemical Reaction to Weak Base Drugs
The IRR model reaction scheme represented in Reaction (2)
from Krieg et al.17 to predict weak acid dissolution was used
to analyze the impact of the slow hydration and dehydration
reactions on bicarbonate buffer by assuming that H2CO3 un-
dergoes an irreversible chemical reaction to form CO2 and H2O.
The chemical reactions that were considered for the weak base
dissolution analysis are shown below:
H+ +OH−
Kw
 H2O (Reaction 11)
B− +H2O
KDb
 BH+OH− (Reaction 12)
B− +H+
K∗1
 BH+H2O (Reaction 13)
B− +H2CO3
K2
 BH+HCO−3 (Reaction 14)
HCO−3 +H2O
KBb
 H2CO3 +OH− (Reaction 15)
H2CO3
kd
 CO2 +H2O (Reaction 16)
The impact of dehydration reaction rate (kd) in the calcula-
tion for the hydroxide ion concentration at the surface of the
dissolving drug appears in Eq. (2). In this model, a simplifying
assumption is that the hydration reaction rate equals zero.
p
[
OH−
]3
0 + q
[
OH−
]2
0 + r
[
OH−
]
0 + s= 0 (2)
p = −DHCO3DOH
q= −DHCO3DH
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h
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h
√
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MATERIALS AND METHODS
Benzoic acid (Sigma–Aldrich, St. Louis, Missouri; >99.5%,
lot #MKBG2270V), ibuprofen (Albermarle, Baton Rouge,
Louisiana; lot #11550-0005), indomethacin (Alexis Biochemi-
cals, San Diego, California; 98%, lot #L25666), 2-napthoic
acid (Sigma–Aldrich; lot #14709KHV), ketoprofen (Sigma–
Aldrich; lot #044K0790), and Haloperidol (TCI, Portland, Ore-
gon; >98.0% lot #D6C3D-R1) were used as received. All other
chemicals used were of analytical grade. Distilled water was
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Table 1. Rotating Disk Dissolution Experimental Parameters Applied to the Weak Acid Drugs Examined at 37°C and Isotonic Solution (Ionic
Strength = 0.154 mol/L)
Drug Ibuprofen Indomethacin Ketoprofen 2-Naphthoic Acid Benzoic Acid
Bulk pH 6.5 6.5 6.5 6.5 6.5
Percent CO2 7–8 7–8 7–8 7–8 6.5–7.5
14–16 14–16 14–16 14–16 11–13
21–22 21–22 24–26 22–25 25–27
33–37
Total buffer concentration
[CO2(aq)]+[HCO3−] (mM)
6.5–7.5 6.5–7.5 6.5–7.5 6.5–7.5 6–7
13–15 13–15 13–15 13–15 10.3–12.1
19.5–20.5 19.5–20.5 22–24 20.5–23.5 23.3–25.2
30.8–34.5
[CO2(aq)]+[HCO3−] 2.9–3.3 2.9–3.3 2.9–3.3 2.9–3.3 2.7–3.1
Bulk solution 5.7–6.6 5.7–6.6 5.7–6.6 5.7–6.6 4.5–5.3
Buffer capacity dn/dpH(mM/pH) 8.6–9.0 8.6–9.0 9.8–10.7 9.0–10.3 10.3–11.1
13.5–15.2
Bicarbonate concentration
[HCO3−] (mM)
5–5.5 5–5.5 5–5.5 5–5.5 4.5–5.2
10–11 10–11 10–11 10–11 7.6–9.0
14.5–15.5 14.5–15.5 16.5–18.0 15–17 17.3–18.7
22.9–25.6
Phosphate buffer concentration
[H2PO4−]+[HPO4−2] (mM)
3.5 2.5 10 10 13
5.2 13 25 25 25
6.95 25 50 50 43.5
13 43.5
25
43.5
Phosphate buffer 1.79 1.28 5.12 5.12 6.66
Bulk solution buffer capacity
dn/dpH(mM/pH)
2.66 6.66 12.81 12.81 12.81
3.56 12.81 25.61 25.61 22.28
6.66 22.28
12.81
22.28
Volume of dissolution medium (mL) 150 100 300 200 300
rpm 100 100 100 100 100
used for all experiments. All dissolution runs were performed
in a jacketed beaker at 37°C. Two dissolution runs were carried
out for each experimental condition described below. Samples
were analyzed using a UV spectrophotometer (Agilent Tech-
nologies, Santa Clara, California; model #61103A). The sam-
ples were obtained using a flow-through system that recycled
the analyzed solution back into the dissolution vessel. The
standard curves were also made using the UV flow through
system.
Dissolution experiments using phosphate buffer were per-
formed in duplicate at pH 6.5 at several different phosphate
concentrations and medium volumes. The exact experimen-
tal parameters can be seen in Tables 1 and 2. Solutions were
made using sodium monobasic phosphate, sodium hydroxide,
and sodium chloride so the ionic strength of the buffer solution
was isotonic. A disc of compressed drug with a tablet diam-
eter of 1 cm was used for ibuprofen, indomethacin, ketopro-
fen, and haloperidol. A compressed disc with a tablet diameter
of 0.472 cm was used for benzoic acid and 2-naphthoic acid.
Differences in volume and tablet diameter used for these ex-
periments were made according to the solubility and predicted
flux of each drug to achieve desirable experimental conditions
(sink conditions and adequate sensitivity for UV analysis). All
experiments were carried out at 100 rpm.
For the rotating disk dissolution experiments in bicarbonate
buffer, different bicarbonate buffer concentrations were pre-
pared by continuously flowing quantities of 100% dry com-
pressed air and 100% carbon dioxide in a 0.9% NaCl solu-
tion at appropriate ratios directly into the distilled water. The
%CO2(aq) in solution was determined using a CO2 monitor (YSI
8500, Yellow Springs, Ohio) and pH was monitored using a pH
meter (Beckman  40, Brea, California). Solid sodium hydrox-
ide or 5N NaOH was added to adjust pH. The exact experimen-
tal parameters can be seen in Tables 1 and 2. Note that the
buffer concentration may be defined either as the bicarbonate
concentration or the sum of bicarbonate and CO2 as shown in
Tables 1 and 2.
The solubility of 2-naphthoic acid was determined by agi-
tating the suspension in 0.1N hydrochloric acid solution while
being kept at 37°C. Samples were filtered before dilution in pH
6.5, 50 mM phosphate buffer.
The flux of the drugs was predicted by applying the mathe-
matical models outlined in this paper and in Krieg et al.17 using
MATLAB (Mathworks, Natick, Massachusetts). The drug and
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Table 2. Rotating Disk Dissolution Experimental Parameters Applied
to the Weak Base Drug Haloperidol at 37°C and Isotonic Solution
(Ionic Strength = 0.154 mol/L)
Drug Haloperidol
Bulk pH 6.0 6.5 7.0
Percent CO2 45 7–8 5
14–16a
22
Total buffer concentration
[CO2(aq)]+[HCO3−] (mM)
20.7 6.5–7.5 12.2
13–15a
20.5
Bicarbonate concentration [HCO3•]
(mM)
9.9 5–5.5 11
10–11a
15
[CO2(aq)]+[HCO3−] 11.9 2.9–3.3 2.5
Bulk solution 5.7–6.6
Buffer capacity dn/dpH(mM/pH) 9.0
Phosphate buffer concentration
[H2PO4−+HPO4−2] (mM)
NA 2.5 NA
13
25
43.5
Phosphate buffer NA 1.28 NA
Bulk solution buffer capacity
dn/dpH(mM/pH)
6.66
12.81
22.28
Volume of dissolution
medium (mL)
75 75 75
rpm 100 100 100
aExperimental parameters that were used for pH 6.5 in bicarbonate buffer in
Figure 7.
buffer properties that were applied to the analysis are given in
Table 3. The predictions using the IRR and CAI models had a
buffer concentration input equal to the bicarbonate concentra-
tion. When the BCE model was applied to bicarbonate buffer,
the buffer concentration was equal to the sum of bicarbonate
and CO2 concentrations. This is because of the assumptions of
each model.
Figure 1. The experimental and predicted flux of ibuprofen in bi-
carbonate and phosphate buffer at multiple concentrations (at pH 6.5
and 37°C). Key: () experimental flux in phosphate buffer; ( )
predicted flux in phosphate buffer (BCE); ( ) experimental flux in bi-
carbonate buffer; ( ) BCE model flux predictions; ( )
IRR model flux predictions; ( ) CAI model flux predictions.
RESULTS
Ibuprofen Results
Figure 1 shows the flux of ibuprofen in phosphate buffer over
a range of buffer concentrations along with theoretical predic-
tions for eachmodel at pH 6.5. The data for the flux of ibuprofen,
in bicarbonate buffer, are also included for comparison purposes
and are described in detail in Krieg et al.17 The rotating disk
flux of ibuprofen in phosphate buffer is accurately predicted
by the simultaneous diffusion and chemical reaction model as
expected. The predictions show that an increase in phosphate
buffer concentration results in a significant increase in the flux
but ibuprofen still serves as a self-buffer and influences sur-
face pH under the conditions studied. Figure 1 shows that the
phosphate buffer concentrations needed to match ibuprofen
Table 3. Drug and Buffer Properties Applied to the Different Mathematical Models
Species
Intrinsic Solubility at
37°C (mol/L) pKa
Diffusion Coefficient
(cm2/s)
Ionic Strength/
Temperature Conditions
for the pKa Values Listed
Benzoic acid 0.033421 4.1922 12.0 × 10−6a Water/25°C22
Ibuprofen 3.30 × 10−418 4.4318 7.93 × 10−6a 0.15/37°C18
Indomethacin 5.963 × 10−6b 4.2723 6.8 × 10−624 0.15/37°C23
Ketoprofen 5.303 × 10−4b 4.0225 9.3 × 10−64 0.15/37°C25
2-Napthoic acid 3.044 × 10−4b 4.2226 9.86 × 10−6a 0.02/25°C26
Haloperidol 3.518 × 10−625 8.3525 6.6 × 10−624 0.15/37°C25
Phosphate 6.818 11.5 × 10−64 0.15/37°C18
Bicarbonate 6.04b,c 14.6 × 10−627 0.15/37°Cb
Carbonic acid 3.5528d 14.6 × 10−627 0.217/37°C28
Carbon dioxide 0.0240317 24.9 × 10−629
Values were taken from literature. Haloperidol solubility and pKa data were taken from USP (2000)5 and used to calculate the intrinsic solubility of haloperidol
based on their reported measured solubility in a pH 4.94 saturated solution.
aDiffusion coefficients were estimated using the Wilke–Chang equation,30 or bmeasured experimentally.
cChemical equilibrium: CO2(aq)+H2OKa H+HCO−3 .
dCarbonic acid chemical equilibrium H2CO3Ka1 H+ +HCO−3 .
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Figure 2. The experimental and predicted flux of indomethacin in bi-
carbonate and phosphate buffer at multiple concentrations (at pH 6.5
and 37°C). Key: () experimental flux in phosphate buffer; ( )
predicted flux in phosphate buffer (BCE); ( ) experimental flux in bi-
carbonate buffer; ( ) BCE model flux predictions; ( )
IRR model flux predictions; ( ) CAI model flux predictions.
dissolution in physiologically relevant bicarbonate buffer are
4–8 mM.
Indomethacin Results
Figure 2 shows the flux of indomethacin in bicarbonate and
phosphate buffer over a range of buffer concentrations along
with theoretical predictions at pH 6.5. The data for the flux
of indomethacin, in bicarbonate buffer, are described in de-
tail in Krieg et al.17 The simultaneous diffusion and chemi-
cal reaction (BCE) model accurately predicts the experimental
flux of indomethacin in phosphate buffer. The calculated pH
at the surface of indomethacin approaches the bulk pH at low
concentrations of phosphate buffer as expected because of the
low-intrinsic solubility of indomethacin that makes it a poor
self-buffer. Bicarbonate is not able to buffer the surface pH
of indomethacin as effectively as phosphate buffer. Therefore,
very low phosphate buffer concentrations (1–2 mM) are needed
to match physiologically relevant bicarbonate buffer. As was
seen for ibuprofen, the slow hydration reaction rate has a sig-
nificant impact on the buffer capacity of bicarbonate and only
the IRR model can accurately predict the flux of indomethacin
in bicarbonate buffer.
Ketoprofen Results
Figure 3 shows the flux of ketoprofen in bicarbonate and phos-
phate buffer over a range of buffer concentrations along with
theoretical predictions at pH 6.5. The data for the flux of ke-
toprofen, in bicarbonate buffer, is described in detail in Krieg
et al.17 The predictions show that an increase in buffer concen-
tration results in a significant increase in the flux. The pre-
dicted flux matches the experimental flux in phosphate buffer.
The experimental flux of ketoprofen in bicarbonate buffer is
only accurately predicted when the IRR model is applied.
Figure 3 shows that phosphate buffer concentrations needed
to match physiologically relevant bicarbonate buffer are ap-
proximately 5–12 mM.
Figure 3. The experimental and predicted flux of ketoprofen in bi-
carbonate and phosphate buffer at multiple concentrations (at pH 6.5
and 37°C). Key: () experimental flux in phosphate buffer; ( )
predicted flux in phosphate buffer (BCE); ( ) experimental flux in bi-
carbonate buffer; ( ) BCE model flux predictions; ( )
IRR model flux predictions; ( ) CAI model flux predictions.
Figure 4. The experimental and predicted flux of 2-napthpoic acid in
bicarbonate and phosphate buffer at multiple concentrations (at pH 6.5
and 37°C). Key: () experimental flux in phosphate buffer; ( )
predicted flux in phosphate buffer (BCE); ( ) experimental flux in bi-
carbonate buffer; ( ) BCE model flux predictions; ( )
IRR model flux predictions; ( ) CAI model flux predictions.
2-Napthoic Acid Results
Figure 4 shows the flux of 2-napthoic acid in bicarbonate and
phosphate buffer over a range of buffer concentrations along
with theoretical predictions at pH 6.5. The predictions show
that an increase in buffer concentration results in a significant
increase in the flux. The solubility of 2-naphthoic acid is similar
to ibuprofen. Therefore, 2-napthoic acid acts similarly as a self-
buffer at the dissolving surface. The predicted flux matches
the experimental flux in phosphate buffer. The experimental
flux of 2-naphthoic acid in bicarbonate buffer is only accurately
predicted when the dehydration reaction rate is incorporated
by applying the IRR model. Figure 4 shows phosphate buffer
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concentrations needed to match physiologically relevant bicar-
bonate buffer are similar to ibuprofen (3–10 mM).
Benzoic Acid
Figure 5 shows the flux of benzoic acid in bicarbonate and phos-
phate buffer over a range of buffer concentrations at pH6.5. The
flux of benzoic acid in phosphate buffer is accurately predicted
by the simultaneous diffusion and chemical reactionmodel. The
predictions and results show that a large increase in buffer con-
centration does not cause a significant increase in the flux. This
is because of the high solubility of benzoic acid that is apparent
in the large flux value for benzoic acid at zero buffer concen-
tration. A highly soluble weak acid drug will lead to a high
concentration of drug at the surface and a high [H+] that limits
the pH change at the surface even in the presence of high-buffer
concentration. In effect, the solubility of benzoic acid very ef-
fectively serves as a self-buffer and controls surface pH under
the conditions studied.
As observed with all of the weak acid drugs, the BCE and
CAI models do not accurately predict the flux of benzoic acid
in bicarbonate buffer. In the case of benzoic acid dissolution
in bicarbonate buffer, it was observed throughout these exper-
iments that gas bubbles continuously formed at the surface of
the dissolving tablet. This very likely affected the hydrodynam-
ics and effective surface area of the dissolving drug available for
dissolution resulted in a poor correlation with the IRR model.
The gas bubbles at the dissolving surface were likely carbon
dioxide. The concentration of CO2 at the surface depends on
the [H+] concentration Eq. (3). When [H+] is sufficiently high,
the CO2 (aq) concentration can exceed its solubility under the
conditions studied and cause CO2 to come out of solution.
[
CO2 (aq)
] =
[
H+
] [
HCO−3
]
Ka1
(3)
Figure 5. The experimental and predicted flux of benzoic acid in bi-
carbonate and phosphate buffer at multiple concentrations (at pH 6.5
and 37°C). Key: () experimental flux in phosphate buffer; ( )
predicted flux in phosphate buffer (BCE); ( ) experimental flux in bi-
carbonate buffer; ( ) BCE model flux predictions; ( )
IRR model flux predictions; ( ) CAI model flux predictions.
The BCE model enables the calculation of the concentration
of carbon dioxide at the surface of the tablet. At the highest
experimental CO2 partial pressure (37% CO2), the BCE model
predicts a nearly saturated solution (98% saturated) of CO2 at
the surface of the tablet. Furthermore, the assumptions made
in the IRRmodel are consistent with the buildup of carbon diox-
ide in the diffusion layer. The IRR model assumes that the con-
centration of carbon dioxide will only increase in the diffusion
layer without an ability to be transformed back into carbonic
acid. Additionally, the high solubility of benzoic acid leads to
a low pH in the diffusion layer that will generate more carbon
dioxide and could cause the concentration of carbon dioxide to
exceed its solubility. Hence, these predictions are very consis-
tent with the IRR model and the hypothesis that the bubbles
formed at the dissolving benzoic acid compact surface are be-
cause of saturated CO2 conditions in the diffusion layer and at
the dissolving surface.
Haloperidol Results
Figure 6 shows haloperidol flux, a weak base, in bicarbonate
and phosphate buffer over a range of buffer concentrations at
pH 6.5. The predictions show that an increase in buffer con-
centration results in a significant increase in the flux. The sol-
ubility of haloperidol is similar to indomethacin and, in the
same way, the low solubility of the drug prevents it from effec-
tively self-buffering the surface pH. The rotating disk experi-
mental flux in phosphate buffer is predicted accurately by the
BCEmodel. The experimental flux of haloperidol in bicarbonate
buffer falls between the BCE model (pKa = 6.04) and the CAI
model (pKa = 3.55). Experimental flux of haloperidol in bicar-
bonate buffer is only accurately predicted when the IRR model
is used for the predictions. The data and predictions show that
for low-solubility drugs, such as haloperidol, it is important
to have accurate physicochemical properties to make accurate
predictions. The parameters used for the haloperidol predic-
tions were obtained from literature and the solubility and pKa
of haloperidol varies significantly in literature.24,25,31–33 Addi-
tionally, the experimental data and predictions in bicarbonate
and phosphate buffer show that phosphate is much better at
Figure 6. The experimental and predicted flux of haloperidol in bi-
carbonate and phosphate buffer at multiple concentrations (at pH 6.5
and 37°C). Key: () experimental flux in phosphate buffer; ( )
predicted flux in phosphate buffer (BCE); ( ) experimental flux in bi-
carbonate buffer; ( ) BCE model flux predictions; ( )
IRR model flux predictions; ( ) CAI model flux predictions.
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Figure 7. The experimental and predicted flux of haloperidol in ap-
proximately 10 mM bicarbonate buffer at bulk pH values 6, 6.5, and 7
at 37°C. Key: ( ) experimental flux; ( ) BCE model flux pre-
dictions; ( ) IRR model flux predictions; ( ) CAI model
flux predictions.
buffering the surface pH. Therefore, very low concentrations
of phosphate buffer would be needed to match bicarbonate
(<1 mM).
Figure 7 shows the experimental and predicted flux of
haloperidol in 10 mM bicarbonate buffer with bulk pH values
of 6, 6.5, and 7. As the bulk pH decreases, the experimental and
predicted flux in bicarbonate increases. This is because of an
increase in H+ in the solution and consequently a decrease in
the surface pH and an increase in the ionized form of the drug
in the diffusion layer, leading to an increase in the overall flux
of the weak base drug. The BCE model overestimates and the
CAI model underestimates the effect that changing the bulk
pH will have on the surface pH and the flux of the drug. The
IRR model accurately predicts experimental flux of haloperidol
in bicarbonate buffer.
DISCUSSION
The dissolution data presented here for weak acid and weak
base drugs illustrate the importance the reaction rates play in
the buffering capacity of bicarbonate in the diffusion layer. If
the hydration and dehydration reaction were effectively instan-
taneous, the dissolution in bicarbonate would have been pre-
dicted to be faster than the dissolution in phosphate buffer in
accordancewith theBCEmodel. As the pH in the diffusion layer
would be lower than 6.5 because of the ionization/dissolution of
the weak acid drug, the pKa of bicarbonate of 6.04 would make
it a better buffer than the phosphate buffer with a pKa of 6.8
at the dissolving drug surface. The predicted curves compar-
ing the BCE bicarbonate buffer model and the BCE phosphate
buffer model demonstrate this. Therefore, matching the buffer
capacity of two different buffers in the bulk solution will not
result in the same dissolution profile because the drug itself
plays an important role in the dissolution rate. For example, a
buffer concentration of 15 mM CO2–bicarbonate buffer in the
bulk solution at pH 6.5 has the same buffer capacity as 13 mM
phosphate buffer at pH 6.5 in the bulk solution. However, the
predictions and experimental results show that matching these
buffer capacities will not lead to matching dissolution rates.
When the slow-hydration reaction of bicarbonate is assumed
to be insignificant in the CO2–bicarbonate buffer system, as
it is in the IRR model, the dissolution all the weak acid and
weak base drugs studied here in bicarbonate buffer is accu-
rately predicted. The impact of the slow hydration reaction
is significant and drastically alters the buffer capacity of the
CO2–bicarbonate buffer system in the diffusion layer adjacent
to the surface of the drug. Comparing the predictions for the
BCE and IRR transport analysis reaction schemes for the CO2–
bicarbonate buffer demonstrates the dynamic nature of bicar-
bonate buffer. For example, the BCE bicarbonate model would
predict that a 10-mM bicarbonate buffer would provide the
same buffering ability in the diffusion layer as approximately
50 mM phosphate buffer at a bulk of pH 6.5. Therefore, when
the reaction time is unlimited (i.e., in the bulk solution) and
the rates of the hydration and dehydration reactions do not
play a limiting role in buffering capacity (i.e., the BCE model),
bicarbonate acts as a strong buffer. However, when a drug is
dissolving and there is a finite reaction time (i.e., in the diffu-
sion layer using the IRR model), bicarbonate has a much lower
buffer capacity that is only partially compensated for by the de-
hydration of H2CO3. This transport/reaction analysis indicates
that bicarbonate is very effective at minimizing changes in the
bulk aqueous phase (e.g., in the intestinal lumen), but the effec-
tiveness of bicarbonate as a buffer becomes significantly altered
in the diffusion layer for dissolving weak acid and weak base
drugs at intestinal pH values.
The flux data also confirms that the IRR model accurately
predicts the experimental flux of weak acid drugs in bicarbon-
ate buffer. It can also be applied to weak base drugs at dif-
ferent buffer concentrations and bulk pH. This has not been
previously shown and is important because many drugs are
weak bases and provides insight into the dissolution of weak
bases in the intestine. Furthermore, the experimental data for
haloperidol and the data presented in Krieg et al.17 demon-
strate the ability of the IRR model to be used under various
experimental conditions (e.g., different bulk pH, drug solubili-
ties, rotational speeds). Results also give good approximations
of the phosphate buffer concentrations needed to match phys-
iologically relevant bicarbonate buffer concentrations for ro-
tating disk dissolution of drugs with varying physiochemical
properties. For the drugs studied in this paper, the phosphate
buffer concentrations needed to match physiologically relevant
bicarbonate buffer were approximately 1–15 mM based on the
experimental data and the IRR model predictions.
Additionally, the data in phosphate buffer further confirm
the accuracy of the filmmodel to predict the dissolution of weak
acid drugs in phosphate buffer and that it can be successfully
applied to weak base drugs that had not been previously shown.
Predicting Physiologically Relevant Phosphate Buffer
Concentrations
Although there have been recent advancements in preparing
bicarbonate buffer and controlling buffer concentration,34 the
process of making bicarbonate buffer is not ideal for performing
dissolution experiments. The experimental data in this paper
and the data in Krieg et al.17 demonstrate that the IRR model
can accurately predict the effect bicarbonate has on buffering
surface pH of weak acid and weak base drugs under rotating
disk dissolution conditions. This paper and previous work also
illustrates the ability to accurately predict rotating disk drug
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Figure 8. The predicted equivalent phosphate buffer concentration needed to match 10.5 mM bicarbonate buffer for weak acid drugs with drug
pKas of 3–8 and weak base drugs with pKas of 5–10 and drug solubilities of 0.1–10−6 M for both. Key: ( ) equivalent buffer predictions
at pH 6 (h = 30 :m); ( ) equivalent buffer predictions at pH 6.5 (h = 30 :m); ( ) equivalent buffer predictions at pH 7 (h =
30 :m); () equivalent buffer predictions for benzoic acid; () equivalent buffer predictions for ketoprofen; ( ) equivalent buffer predictions for
ibuprofen; (♦) equivalent buffer predictions for indomethacin; (X) equivalent buffer predictions for haloperidol.
dissolution in phosphate buffer using the film model assuming
chemical equilibrium is achieved instantaneously.2,4 Therefore,
applying each of these models to their respective buffer system
will provide accurate estimations for phosphate buffer concen-
trations that will simulate physiologically relevant bicarbonate
buffer.
To estimate phosphate buffer concentrations needed to
match physiologically relevant bicarbonate buffer, drug pKa
and solubility were varied and the IRR model was applied as-
suming an aqueous diffusion coefficient of 7.9 × 10−6 cm2/s. For
weak acids, the drug pKa was varied from 3 to 8, and for weak
bases the drug pKa was varied from 5 to 10. The drug solubil-
ity was varied from 10−1 to 10−6 M. The physiologically rele-
vant bicarbonate buffer chosen for the predictions was 15%CO2
(10.4 mM bicarbonate concentration) at pH 6.5 as representa-
tive of small intestinal conditions.35 The diffusion layer thick-
ness for these predictions was chosen as 30 :m based on the
work of Hintz and Johnson.36
The relationship between equivalent phosphate buffer con-
centration and the pKa of weak acid drugs, pKw–pKa for weak
base drugs, and log(drug solubility) is shown in Figure 8. For
weak acid drugs, when the [pKa–log(drug solubility)] is plotted
versus the equivalent phosphate buffer concentration neces-
sary to match physiologically relevant bicarbonate buffer, a sin-
gle curve is obtained at each bulk pH as shown in Figure 8. The
same is true for weak base drugs when [pKw−pKa−log(drug
solubility)] is plotted versus equivalent phosphate buffer as
shown in Figure 8. This is because of the relationship between
the weak acid drug Ka (for a weak base: Kw−Ka) and the solu-
bility of the drug in the cubic equation of the IRR model. These
two parameters only appear in the cubic equation as being mul-
tiplied together. Therefore, if one parameter is decreased by an
order of magnitude while the other is increased by an order of
magnitude, this will result in the same solution for the cubic
equation and pH at the surface of the drug. This figure provides
an overview of the impact of drug solubility, pKa, and bulk pH
under what could be considered physiologically relevant buffer
concentrations in the intestinal tract.
Predictions at bulk pH of 6.0, 6.5, and 7.0 show that phos-
phate buffer concentrations needed to match physiologically
relevant bicarbonate buffer are higher for both weak acid and
weak base drugs at pH 6 and lower at pH 7. This is because
of the low pKa for the ionization reaction of carbonic acid (pKa
= 3.55), which is used in the IRR model. As the bulk pH is
lowered toward 3.55, the buffering capacity of bicarbonate in-
creases. This is evident in the case of weak acid drugs. There is,
however, a wide range of equivalent phosphate buffer concen-
trations needed to match weak acid drugs (1–95 mM) depend-
ing on the bulk pH and drug properties (i.e., solubility and pKa).
As the drug pKa increases and the drug solubility decreases for
weak acid drugs, the phosphate buffer concentration needed to
provide the same buffer effect decreases. However, when consid-
ering representative BCS class 2a drugs, such as ketoprofen,
ibuprofen, and indomethacin shown in Figure 8, the equiva-
lent phosphate buffer concentrations fall into the range of 1–
25mM. For example, ibuprofen is predicted to require an equiv-
alent phosphate buffer concentration of approximately 11 mM
at pH 6 and approximately 2 mM at pH 7.
In the case of weak base drugs, the matching phosphate
buffer concentration for physiologically relevant bicarbonate
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buffer is less than 2 mM for all drug pKa values and solubilities
evaluated. This is because of weak base drugs forming OH− at
the surface of the dissolving drug that increases the pH and
makes the bicarbonate buffer relatively ineffective. The CAI
reaction pKa is much lower than the pH at the surface so the
irreversible reaction provides only aminor increase in buffer ca-
pacity and makes bicarbonate a very poor buffer for weak base
drugs. Therefore, very little phosphate buffer concentration is
needed to decrease the pH at the surface of the dissolving weak
base drug to have the same effect as physiologically relevant
bicarbonate buffer.
The predictions of phosphate buffer concentrations that
match physiologically relevant bicarbonate buffer offer a dis-
solution medium that can better simulate the impact of bicar-
bonate in the small intestine. The phosphate concentrations
needed are both drug and pH dependent. Therefore, based on
this work, each drug will require a phosphate buffer concentra-
tion dependent upon its properties. However, given the intrinsic
solubility and the pKa of the drug, this work allows for an es-
timate of a phosphate buffer concentration necessary to match
dissolution in bicarbonate buffer.
The plots for equivalent phosphate buffer are made assum-
ing an idealized experimental situation where the pH in the
bulk solution and the diffusion layer thickness are constant.
However, for particle dissolution, this may not be the case. As
a weak acid or weak base drug dissolves, the bulk pH may
change, especially in cases of high-dose drugs. Although the
CO2–bicarbonate buffer may be expected to maintain a rela-
tively constant pH in the bulk solution, this may not be the
case for an equivalent phosphate buffer with low-buffer capac-
ity. The equivalent phosphate buffer is that which is predicted
to match the impact that bicarbonate has on buffering the pH
in the diffusion layer and at the dissolving drug surface. As bi-
carbonate is a comparatively ineffective buffer in the diffusion
layer, the predicted matching phosphate buffer will also be in-
effective compared to phosphate buffer concentrations that are
commonly used for dissolution testing. However, the low-buffer
capacity of phosphate will be observed in both the diffusion
layer and the bulk solution. This problem could be overcome by
maintaining a relatively constant bulk pH through titration.
Another consideration that must be taken into account is that,
as a drug particle is dissolving, the diffusion layer thickness of
the particle may be considered to change.36–38 The bicarbonate
buffer model and the data for flux of ibuprofen at different ro-
tational speeds (different diffusion layer thickness) in Krieg
et al.17 shows that the predicted pH at the surface of the
drug is dependent on the diffusion layer thickness. This aspect
makes the selection of an appropriate diffusion layer thickness
a significant parameter for particle dissolution in bicarbonate
buffer. Of course, the dosage form and excipients could affect
disintegration and dissolution. This could have a significant im-
pact on the phosphate buffer concentration that best simulates
physiologically relevant bicarbonate buffer.
CONCLUSIONS
The experimental data obtained from rotating disk dissolu-
tion shows that the simultaneous diffusion and chemical reac-
tion model accurately predicts drug flux where “instantaneous”
chemical reactions occur as is the case for phosphate buffer.
In the case of bicarbonate buffer, the predicted flux and ex-
perimental results show the importance of reaction kinetics in
buffering the pH in the diffusion layer and at the surface of
the dissolving drug. The dissolution results for the weak acids
ibuprofen, indomethacin, 2-naphthoic acid, ketoprofen, benzoic
acid, and the weak base haloperidol demonstrate that the ex-
perimental flux in bicarbonate buffer cannot be predicted ac-
curately by assuming that chemical equilibrium is instantly
achieved. Therefore, the reaction rates must be taken into ac-
count. Because of the slow reaction rate between CO2 and
H2O, the BCE model overestimates and the CAI model un-
derestimates the impact of bicarbonate buffer throughout the
convective-diffusion layer and at the surface of the tablet. We
show that the slow hydration and dehydration reactions can be
accounted for by assuming that CO2 does not react with H2O in
the convective-diffusion layer, whereas H2CO3 undergoes an
irreversible chemical reaction forming CO2 and H2O in the
convective-diffusion layer. This unique attribute of the bicar-
bonate buffer-diffusion-reaction system can accurately predict
drug dissolution in bicarbonate buffer.
Matching the dissolution rate (flux) of weak acid and weak
base drugs in phosphate and bicarbonate buffer systems is pos-
sible, but it is a complex function of buffer pH and pKa, drug
pKa and solubility, and diffusion layer thickness. The accuracy
of the IRR model to predict rotating disk dissolution in bicar-
bonate buffer allowed for predictions of equivalent phosphate
buffer concentrations that matched physiologically relevant bi-
carbonate buffer for both weak acid and weak base drugs. An
important conclusion of this work is that, although it is pos-
sible to identify an equivalent phosphate buffer for a drug, a
precise match for dosage form testing is challenging because of
the complex nature mentioned here. However, this paper pro-
vides a simple way to identify phosphate buffer concentrations
that may provide a better dissolution media to simulate the
dissolution of weak acid and weak base drugs in vivo. If the
intrinsic solubility of the drug and the drug pKa are known,
Figure 8 provides a useful guide to develop a dissolution proto-
col using phosphate buffer concentrations that may be more in
vivo relevant.
It appears that low phosphate buffer concentrations (1–
25 mM) are often more physiologically relevant and may bet-
ter simulate the impact of bicarbonate buffer on the dissolu-
tion of weak acid drugs. For weak base drugs, extremely low
phosphate buffer concentrations (<2 mM) would be needed to
match physiologically relevant bicarbonate buffer. These pre-
dicted equivalent phosphate buffer concentrations suggest that
the current phosphate buffer concentrations used for dissolu-
tion testing (often 50 mM) likely do not accurately reflect the
dissolution media and conditions that a drug will experience in
the intestine.
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